Scorpius Holdings (SCPX) AI Stock Analysis

2,639 Followers

Scorpius Holdings

(Other OTC:SCPX)

Select Model

Rating:43Neutral

Price Target:$0.01▲(1566.67% Upside)

Action:reiterated

Date:01/30/26

Scorpius Holdings faces severe financial distress, with critical losses, high leverage, and cash burn leading to bankruptcy risk. The stock's technicals confirm a strong downtrend, and recent corporate events further erode the business foundation. Valuation offers no support. The overall score reflects these substantial risks.

Positive Factors

Diversified business modelScorpius operates across technology, real estate and renewable energy and earns fees, dividends and capital gains. This multi‑stream model reduces reliance on a single market cycle and gives management flexibility to reallocate capital to higher-growth portfolio areas over the next 2–6 months and beyond.

Negative Factors

Very high leverageA 4.53 debt‑to‑equity ratio indicates substantial leverage that elevates refinancing, interest and covenant risk. High structural leverage limits strategic flexibility, increases default probability if cash flow remains weak, and magnifies losses to equity holders during prolonged revenue weakness.

Scorpius Holdings (SCPX) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $12.23K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.0
Beta (1Y): -7.06
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 91
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Scorpius Holdings Business Overview & Revenue Model

Company Description

Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and sta...

How the Company Makes Money

Scorpius Holdings generates revenue through multiple streams, primarily from its strategic investments in various sectors. The company earns income by acquiring stakes in high-potential startups and established businesses, benefiting from capital app...

Scorpius Holdings Financial Statement Overview

Summary

Severe financial stress: income statement score 15, balance sheet score 5, cash flow score 20 reflect persistent losses, high debt, and negative cash flow. Modest improvements overshadowed by critically low cash and negative equity, raising bankruptcy concerns.

Income Statement

15Very Negative

Balance Sheet

5Very Negative

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2025	Dec 2023	Mar 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.76M	6.24M	6.99M	5.98M	2.11M	2.95M
Gross Profit	367.51K	3.05M	-2.22M	-420.02K	1.42M	2.95M
EBITDA	-23.22M	-26.22M	-33.99M	-38.26M	-34.94M	-24.59M
Net Income	-25.18M	-32.81M	-45.22M	-43.43M	-35.07M	-26.05M
Balance Sheet
Total Assets	20.77M	39.18M	51.04M	104.40M	120.96M	124.19M
Cash, Cash Equivalents and Short-Term Investments	600.79K	2.38M	2.39M	39.03M	96.38M	111.77M
Total Debt	18.12M	28.55M	14.04M	9.30M	1.93M	1.85M
Total Liabilities	27.75M	37.50M	22.74M	31.96M	8.93M	8.70M
Stockholders Equity	-1.33T	6.30M	31.40M	73.92M	113.11M	116.24M
Cash Flow
Free Cash Flow	-9.75T	-26.88M	-33.52M	-25.82M	-40.03M	-22.36M
Operating Cash Flow	-6.78T	-26.01M	-31.53M	-5.70M	-38.13M	-22.02M
Investing Cash Flow	77.44B	1.21M	32.24M	10.99M	9.77M	-95.42M
Financing Cash Flow	6.19T	25.64M	-8.95M	-4.91M	25.49M	119.33M

Scorpius Holdings Risk Analysis

Scorpius Holdings disclosed 48 risk factors in its most recent earnings report. Scorpius Holdings reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Even though the 2024 Reverse Stock Split increased the market price of our common stock, there can be no assurance that our increased stock price will remain at a price that will be sufficient in order to meet any continued requirements and policies of the NYSE American or that our common stock will remain listed on the NYSE American.Q3, 2024

2.Even though the 2024 Reverse Stock Split increased the market price of our common stock, there can be no assurance that our increased stock price will remain at a price that will be sufficient in order to meet any continued requirements and policies of the NYSE American or that our common stock will remain listed on the NYSE American.Q2, 2024

3.Following the 2024 Reverse Stock Split, the resulting market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our common stock may not improve.Q2, 2024

Scorpius Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SCPX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	45Neutral	$688.79K	0.00	-23.86%	―	143.06%	94.98%
SCPX	43Neutral	$12.23K	-0.00	<0.01%	―	―	―

* Healthcare Sector Average

Performance Comparison

SCPX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SCPX	Scorpius Holdings, Inc.	0.01	0.00	0.00%
SCNI	Scinai Immunotherapeutics Ltd. Sponsored Adr	0.44	-9.18	-95.41%
ADTX	Aditxt, Inc.	0.04	-915.80	-100.00%
CERO	Cero Therapeutics Holdings, Inc.	0.01	-0.06	-86.30%
PBM	Psyence Biomedical Ltd.	3.09	-14.97	-82.89%
CDT	Cdt Equity Inc.	0.44	-273949.59	-100.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 29, 2026

Scorpius Holdings AI Stock Analysis